- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00364585
A Prospective Evaluation of the GreenLight Model 120 Laser
16 de enero de 2008 actualizado por: Weill Medical College of Cornell University
A Prospective Evaluation of the GreenLight Model 120 Laser System for the Treatment of Benign Prostatic Hyperplasia
The purpose of this study is to evaluate the performance of the GreenLight™ model 120 delivering higher average power to allow for more flexibility in the working distance of the delivery device with the same power density to tissue as that of the current GreenLight model.
In addition this study will examine the Laserscope GDD (guided delivery device) that has been designed exclusively for use with the GreenLight™ model 120.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
Benign Prostatic Hyperplasia (BPH) refers to a medical condition which occurs in aging men where the prostate gland is enlarged preventing the free flow of urine.
This causes symptoms of frequent urination, constant feeling of urgency to go to the bathroom, and difficulty passing urine due to the obstruction caused by the enlarged gland.
The incidence (number of new cases) of BPH increases from 40% among males between the ages of 50 and 60 years to 90% among males older than 80 years of age.
Treatment of BPH is currently undergoing intense scrutiny due to the cost and morbidity (complications and disability due to the procedure) associated with the "gold standard" treatment, Transurethral Resection of the Prostate (TURP).
The TURP procedure has established its place as a standard of care for BPH due to its exceptional clinical efficacy and established long-term durability.
Despite the clinical prowess of TURP, there remain significant concerns regarding the relatively high incidence of postoperative morbidity and the significant economic burden on world healthcare systems.
Laser vaporization prostatectomy, on the other hand, has developed into a relatively new technological advance that has been utilized with favorable outcomes for more than a decade.
Tipo de estudio
Intervencionista
Inscripción
20
Fase
- Fase 4
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
New York
-
New York, New York, Estados Unidos, 10021
- New York-Presbyterian Hospital Cornell Univeristy
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
40 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
Sí
Géneros elegibles para el estudio
Masculino
Descripción
Inclusion Criteria:
- Subjects must be male and over the age of 40 years.
- Subjects must present with symptomatic/obstructive symptoms secondary to BPH requiring surgical intervention, diagnosed using standard clinical practices (uroflowmetry).
- Subjects must present with LUTS secondary to BPH > 3 months in duration.
- IPPS symptom score value of > 12.
- Prostate size, as measured by transrectal ultrasonography, between 15 and 300 cc.
- Subjects that are in retention may be enrolled in the study provided that it is documented the primary cause of the retention is BPH.
- ASA classification of physical status, class 1-3.
- Subjects must read, understand, and sign the Informed Consent.
- Subjects must be willing and able to comply with all follow-up requirements.
Exclusion Criteria:
- Unstable cardiopulmonary disorder, previously or recently diagnosed by standard methods.
- Subjects with a recent myocardial infarction or coronary artery stent placement.
- Subjects with systemic diseases that cause significant neurogenic lower urinary dysfunction.
- Subjects who have had major pelvic fractures that involved damage to the external urinary sphincter.
- Subjects who have recently completed definitive radiation therapy for prostate cancer.
- Subjects with prostate cancer who are considering brachytherapy (radioactive seed implantation) or cryotherapy as part of their definitive treatment.
- Subjects must not have active localized or systemic infections; including active urinary tract infection.
- Subjects with confirmed atonic bladders and/or neurogenic bladders, reflex dyssynergia, detrusor hyporeflexia/areflexia.
- Subjects diagnosed with active urethral strictures, bladder neck contracture, acute prostatitis affecting bladder function.
- Serum prostate specific antigen level > 4 ng/ml, requiring prostate needle biopsy, and resultant positive pathology for malignancy of the prostate.
- Subjects with confirmed or suspected malignancy of the prostate or bladder.
- Subjects with renal ectasia by renal ultrasound.
- Immunocompromised subjects and deemed unfit for laser vaporization as determined by the attending physician.
- Any disorder or conditions of the subject that the investigator believes will contraindicate their inclusion in the study.
- Subjects who refuse to sign the Informed Consent document and/or comply with all follow-up requirements.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
|---|
|
To evaluate the effectiveness of the GreenLightÔ Model 120 Laser for the treatment (PVP)
|
Medidas de resultado secundarias
Medida de resultado |
|---|
|
To evaluate the effectiveness of the Laserscope GDD
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Alexis Te, MD, Cornell University
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de mayo de 2006
Finalización del estudio (Actual)
1 de abril de 2007
Fechas de registro del estudio
Enviado por primera vez
11 de agosto de 2006
Primero enviado que cumplió con los criterios de control de calidad
14 de agosto de 2006
Publicado por primera vez (Estimar)
15 de agosto de 2006
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
17 de enero de 2008
Última actualización enviada que cumplió con los criterios de control de calidad
16 de enero de 2008
Última verificación
1 de enero de 2008
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 0604008494
- 0000022806
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .